Brief: Crescita Announces Licensing Agreement For Pliaglis In China
05/11/2020 13:33
Nov 5 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* CRESCITA ANNOUNCES LICENSING AGREEMENT FOR PLIAGLIS® IN
CHINA
* CRESCITA THERAPEUTICS - EXCLUSIVE AGREEMENT WITH
JUYOU-BIOTECHNOLOGY CO. LTD FOR COMMERCIALIZATION AND
DEVELOPMENT OF PLIAGLIS IN MAINLAND CHINA
* CRESCITA THERAPEUTICS INC - AS PART OF LICENSE AGREEMENT,
CRESCITA WILL RECEIVE AN UPFRONT PAYMENT IN CASH OF US$125,000
* CRESCITA THERAPEUTICS - AS PART OF LICENSE AGREEMENT,
CRESCITA
WILL BE ELIGIBLE FOR REGULATORY AND SALES MILESTONES OF UP TO
US$1.0 MILLION AND US$1.8 MILLION
Source text for Eikon: ID:nCNWwLf7Ma
Further company coverage: CTX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium